Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I've reported him too for spreading false info. about legal case against the company
From the RNS: "The Company has received indicative support for the Fundraising from certain of its largest shareholders. All of the Directors have also indicated they will participate in the Fundraising."
Nice chunky buys just gone through. This should bounce back to placing price or 40s from here
TroytoTiber, Gynia Holdings is the company’s major shareholder and it holds 82.66% of the shares so there isn’t many shares out there for public to trade which can results in significant drops similar to what we witnessed over the past couple of days or rapid rebounds
I just added, the most recent trading update looks decent , the main shareholder Gynia Holdings holds 82.66% of the shares, which means limited shares are available for public . Consequently, small trading volumes could cause significant drops or rapid rebounds in the share price. Currently, it's heavily oversold across daily, weekly, and monthly tech charts, so I see the share price at least double in the short term.
The asset is significantly oversold based on the daily and weekly technical charts and it's NT to buy at the moment. To me, it seems like this drop was a deliberate move to trigger any remaining stop losses before the results are announced. I will buy here and hold for the results
From the latest trading update:
Business Metrics:
· Cash: $13.9m as of 31 December 2023
· Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22
o Accrufer® revenue: $11.6m, a 3.1x increase over FY22
o Ex-U.S. revenue: $1.5m
o Other income revenue including Viatris milestone payments: $4.4m
· U.S. Q4 2023 Revenue: $4.3m
· Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023
· Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22
It seems someone is accumulating shares at these low prices , near all-time lows causing the share price to repeatedly cross the 140 line . Whenever the share price starts to rise to the 140s, they target the BID to bring it back down and repeat the cycle. It's likely to rebound soon ; you can only squeeze so much from a dry lemon.
Recording of ITM POWER PLC Interim Results presentation, along with responses to questions that were answered by the company has just been published:
Link to the presentation:
https://www.investormeetcompany.com/investor/meeting/interim-results-273/presentation
Link to the Q&A :
https://www.investormeetcompany.com/meetings/interim-results-273
PRESENTERS:
Answered by:
Dennis Schulz - CEO
Andy Allen - CFO
Justin Scarborough - Head of Investor Relations
I watched the latest video call and they said the available cash is sufficient to cover them until probability early next year .
From the latest trading update :
Cash: $13.9m as of 31 December 2023
For the year ended December 31, Shield said it had delivered USD17.5 million in revenue, up nearly three-fold from USD6.2 million in 2022.
28 Sep 2023 RNS:
The Company is also pleased to announce that it has secured a US$20m senior secured debt facility from SWK (the "SWK Financing"), a life science-focused specialty finance company catering for small and mid-sized commercial-stage companies.
The sp is climbing back up :)
Did I read it correct?
- Retail Offer shall not exceed £200,000. ( available for individual shareholders- aka the minions)
-A placing and subscription to raise approximately £2.0 million - from whom?? The company’s Major shareholders? So I take it this placing isn’t available for individual shareholders ?
The rapid decline in share price coupled with AOP Health's significant stake as the company closed the year with total sales of $17.5 million, a significant increase from $6.2 million a year prior, largely driven by robust demand for its iron deficiency treatment, Accrufer, suggests to me a potential imminent takeover. If you examine this article, you'll notice parallels between the current scenario and the situations preceding AOP's takeovers of Amomed and SciPharm.
In May 2023, AOP Health made a cash takeover bid of £46.1 million (equivalent to 6.2 pence per share) for Shield Therapeutics plc (Shield), which represents twice the current share price. I am confident that if AOP Health were to make the same offer tomorrow, they would likely secure the necessary votes from the majority of other shareholders.
*AOP Orphan takes over two healthcare companies:
https://www.aop-health.com/global_en/press/press-releases/rare-disease-pioneer-aop-orphan-takes-over-two-health-care-companies-strengthening-its-position-in-europe-as-well-as-vienna-as-a-research-and-business-hub/